Taizhou, China

Yu Jing

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Location History:

  • Jiangsu, CN (2017)
  • Taizhou, CN (2018)
  • Suzhou, CN (2022 - 2024)

Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Yu Jing: Innovator in Pharmaceutical Advancement

Introduction

Yu Jing, a prolific inventor based in Taizhou, China, has made significant contributions to the field of pharmaceutical innovation. With a total of seven patents to his name, Jing's work primarily focuses on developing compounds that have the potential to treat various diseases, particularly cancer.

Latest Patents

Among his notable inventions are two recent patents that showcase his commitment to tackling challenging medical conditions. The first patent is titled "Tricyclic Compounds as BCR-ABL Inhibitors". This disclosure introduces compounds represented by a specific formula, contributing to the treatment of cancers by inhibiting BCR-ABL—a crucial target in certain cancer therapies.

The second patent, "Macrocyclic Indoles as Mcl-1 Inhibitors", delineates compounds effective in treating conditions responsive to Mcl-1 inhibition, again focusing on cancer treatment. These patents reflect his innovative approach and dedication to developing effective solutions to serious health issues.

Career Highlights

Yu Jing's career includes valuable experience with several companies in the pharmaceutical sector. Notably, he has contributed significantly at Shenyang Sunshine Pharmaceutical Co. Ltd. and Ascentage Pharma (Suzhou) Co., Ltd. His roles at these organizations have allowed him to push the boundaries of innovation in drug development.

Collaborations

Throughout his career, Yu Jing has collaborated with esteemed colleagues such as Yunlong Zhou and Lingling Jiao. These partnerships have enhanced his research and development efforts, leading to the creation of impactful pharmaceutical compounds.

Conclusion

In conclusion, Yu Jing stands out as an influential inventor in the pharmaceutical industry, with a strong track record of innovation. His latest patents not only exemplify his expertise in creating BCR-ABL and Mcl-1 inhibitors but also highlight his dedication to improving cancer treatment options. With a continued focus on impactful research, Yu Jing's contributions will likely play a pivotal role in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…